Monday, August 24, 2009
8:00am Pre-Conference Registration & Morning Coffee
Pre-Conference Short Courses*
(SC1) OPTIMIZING MEDIA: ACHIEVING SUPER SOUP
9:00am-12:00pm
Experts agree that optimizing media is a key component for increasing cell density. This workshop covers the details necessary for achieving Super Soup, from oxygen uptake to nutrient feed and beyond. Join with your colleagues and media experts as they reveal solutions for enhancing cell culture media in the quest to achieve ever higher yields.
Instructors:
Timothy Fawcett, Ph.D., Director, The BioTechnical Institute of Maryland, Inc.
Ali Khademhosseini, Ph.D., Professor, Health Sciences & Technology, Harvard Medical School
Paul J. Price, Ph.D., Chief Scientific Officer, D Finitive Cell Technologies Inc.
Instructor Bio Sketches:
Dr. Timothy Fawcett
Dr. Fawcett earned his undergraduate degree in Biochemistry from the University of New Hampshire, and his doctorate in Biochemistry from Louisiana State University. Prior to joining BTI in May 2001, he was Training Center Manager of Life Technologies, Inc. / Invitrogen. There he wrote, developed, and presented workshops designed to teach medical doctors, principal investigators, and laboratory technicians in areas such as cell culture, recombinant DNA, and protein expression through a combination of lecture and laboratory exercises. Dr. Fawcett has investigated molecular responses to cellular stress at the National Institute on Aging, and the National Institutes of Health in the Laboratory on Gene Expression and Aging. In addition, he consults in the industry. As Director of The BioTechnical Institute of Maryland, Dr. Fawcett leads BTI's Workshop Program and assists with curriculum development.
Dr. Ali Khademhosseini
Ali Khademhosseini is an Assistant Professor of Medicine and Health Sciences and Technology at Harvard-MIT's Division of Health Sciences and Technology and the Harvard Medical School. His research is based on developing micro- and nanoscale technologies to control cellular behavior with particular emphasis in developing microscale biomaterials and engineering systems for tissue engineering and drug delivery. He has published 2 edited books, 80+ peer reviewed papers, 20 book chapters, 100+ abstracts, and 17 issued or pending patents. He has also been invited to give over 100 seminars world-wide. His accomplishments have been recognized by a number of awards including the Outstanding Undergraduate Research (UROP) mentor at MIT (2004), the Outstanding Researcher in Polymer Science by OMNOVA / MIT (2005) and the Coulter Foundation Early Career Award (2006). Also, he won the BMW Scientific Award (2007), one of the most prestigious international young innovator awards and the ACS Victor K. LaMer award (2007) for his doctoral thesis. In 2007, he was recognized as one of the top young innovators (TR35) by the Technology Review Magazine. He has also been the recipient of the NSF CAREER award (2009), as well as the Early Career awards of the University of Toronto’s Engineering School - class of 7T6 (2009) and the IEEE-EMBS society (2008), which is the largest international organization for biomedical engineers. He received his Ph.D. (2005) in bioengineering from MIT under the supervision of Prof. Robert Langer, and MASc (2001) and BSc (1999) in chemical and biomedical engineering from the University of Toronto.
Dr. Paul J. Price
I have been active in the areas of cell culture and media development since 1958. I received my PhD from the George Washington University with majors in Cell Biology, Biochemistry and Virology, and I am currently the Chief Scientific Officer of D-Finitive Cell Technologies (DCT), a specialty cell media company. I am also on the Scientific Advisory Board and a consultant to Sigma-Aldrich, Regenerative Medicine and Research Cell Culture and an Adjunct Professor at the Medical University of South Carolina, Department of Regenerative Medicine. Previously I was a Branch Chief in the Center for Infectious Diseases at the CDC and later founder and Executive Vice-President of Hycor Biomedical (later called Stratagene). As part of R&D at GIBCO Invitrogen/Life Technologies, I helped design and develop much of their specialized media for the culture of neurons, stem cells and other mammalian cells, including those used in Bio-Production. As CSO of DCT, I have developed numerous animal-origin-free formulations for many of the same cell types. I have been an active member of the Society for In Vitro Biology since 1959 and a member of their Board since 1998 and Society President from 2006-2008. I have been a reviewer for “In Vitro” and other journals, and an outside expert for grant reviews for the NCI.
(SC2) PUBLISH AND PERISH?: COMMON PITFALLS AND MISCONCEPTIONS REGARDING PATENTS
9:00am-12:00pm
Instructor: Sunit Talapatra, J.D., Ph.D., Foley and Lardner LLP
Whether seeking proteins or optimizing culture conditions, scientists add to our public knowledge by seeking solutions to “cutting-edge” problems. Many of these solutions can benefit from patent protection, but the opportunity is often inadvertently forfeited by standard practices of scientists, for example, publishing. This short course will provide the bench scientist with the information needed to assure that the research can be patented in a timely and cost-effective way.
- Introduction to intellectual property, including patents
- How to structure/design your experiments for efficient patenting
- What to disclose to your technology transfer office or patent attorney
- When to contact your technology transfer office or patent attorney
BIO - SUNIT TALAPATRA
Dr. Talapatra is an associate with Foley & Lardner LLP. He is a member of the Biotechnology & Pharmaceutical Practice and the Nanotechnology Industry Team. He specializes in preparing and prosecuting patent applications in the fields of biotechnology, biochemistry, pharmaceuticals, and chemistry. In addition, he assists in patentability, infringement, and freedom to operate investigations. Dr. Talapatra has significant experience in the areas of cell biology, virology, immunology, bioinformatics and organic synthesis.
Prior to joining Foley, Dr. Talapatra was a patent agent with Katten Muchin Zavis Rosenman.
Dr. Talapatra earned his J.D. degree from The George Washington University in 2007. He received his Ph.D. in cell and molecular biology from the University of Pennsylvania (2002). He received his M.S. in biochemistry and molecular biology from the University of Chicago (1999) and his B.S. in chemistry from the University of California at Los Angeles (1995). Dr. Talapatra’s graduate work in cancer biology, conducted under the guidance of Dr. Craig Thompson, resulted in the identification of novel proteins and mechanisms in the regulation of cell survival.
Dr. Talapatra is admitted to practice in Virginia and the District of Columbia and before the United States Patent and Trademark Office.
Publications:
• Plas DR, Talapatra S, Thompson CB, et al., Akt and Bcl-xL Promote Growth Factor-independent Survival through Distinct Effects on Mitochondrial Physiology, J. Biol. Chem., 276(15), 2001, 12041-48
• Talapatra S and Thompson CB, Growth Factor Signaling in Cell Survival: Implications for Cancer Treatment, J. Pharm. Exp. Therapeutics, 298(3), 2001, 873-8
• Talapatra S, Thompson CB, et al., Elongation Factor-1 alpha Is a Selective Regulator of Growth Factor Withdrawal and ER Stress- induced Apoptosis, Cell Death Differ., 9(8), 2002, 856-61
• Karnauskas R, Talapatra S, and Rudin C, et al., Bcl-xL and Akt Cooperate to Promote Leukemogenesis In Vivo, Oncogene, 22(5), 2003, 688-98
*Separate Registration Required
